Instrument Inactif

Communiqués Momenta Pharmaceuticals, Inc.

Actions

MNTA

US60877T1007

Recherche biotechnologique et médicale

Communiqués

02/10/20	Momenta Pharmaceuticals : Announces Completion of Proposed Sale to Johnson & Johnson	AQ
01/10/20	MOMENTA PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
01/10/20	Momenta Pharmaceuticals : Announces Completion of Proposed Sale to Johnson & Johnson	AQ
01/10/20	Momenta Pharmaceuticals Announces Completion of Proposed Sale to Johnson & Johnson	GL
16/09/20	Momenta Pharmaceuticals : Announces Expiration of Hart-Scott-Rodino Waiting Period in Connection with Proposed Sale to Johnson & Johnson	AQ
15/09/20	Momenta Pharmaceuticals : Announces Expiration of Hart-Scott-Rodino Waiting Period in Connection with Proposed Sale to Johnson & Johnson	AQ
15/09/20	Momenta Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period in Connection with Proposed Sale to Johnson & Johnson	GL
20/08/20	MOMENTA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Momenta Pharmaceuticals, Inc. - MNTA	BU
19/08/20	MOMENTA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of MNTA and Encourages Investors to Contact the Firm	BU
19/08/20	MOMENTA PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
19/08/20	Momenta Enters Definitive Agreement with Johnson & Johnson	GL
19/08/20	Momenta Pharmaceuticals : Enters Definitive Agreement with Johnson & Johnson	AQ
10/08/20	MOMENTA PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
10/08/20	Momenta: 2Q Earnings Snapshot	AQ
10/08/20	Momenta Pharmaceuticals Reports Second Quarter 2020 Financial and Operating Results	GL
03/08/20	Momenta Pharmaceuticals Announces Date of Second Quarter 2020 Financial Results Conference Call and Webcast	GL
28/07/20	Momenta Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Nipocalimab in HDFN	GL
24/06/20	MOMENTA PHARMACEUTICALS INC : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
16/06/20	Momenta Pharmaceuticals : Announces Positive Topline Data from Interim Analysis of Phase 2 Vivacity-MG Study of Nipocalimab (M281)	AQ
15/06/20	MOMENTA PHARMACEUTICALS INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
15/06/20	Momenta Pharmaceuticals Announces Positive Topline Data from Interim Analysis of Phase 2 Vivacity-MG Study of Nipocalimab (M281) in Generalized Myasthenia Gravis (gMG)	GL
07/05/20	MOMENTA PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
07/05/20	Momenta: 1Q Earnings Snapshot	AQ
07/05/20	Momenta Pharmaceuticals Reports First Quarter 2020 Financial and Operating Results	GL
23/04/20	Momenta Pharmaceuticals Announces Date of First Quarter 2020 Financial Results Conference Call and Webcast	GL